新冠肺炎对肾移植受者的影响

IF 1.1 Q4 IMMUNOLOGY
Ganesan Geethanjali, E. Ramprasad, Sekar Manikantan, M. Jayakumar
{"title":"新冠肺炎对肾移植受者的影响","authors":"Ganesan Geethanjali, E. Ramprasad, Sekar Manikantan, M. Jayakumar","doi":"10.34172/ipp.2023.39489","DOIUrl":null,"url":null,"abstract":"Introduction: It was essential to explore immunosuppressant management strategies and potential clinical variables associated with COVID-19 related mortality in order to provide insight for clinicians attempting to manage kidney transplant recipients during the ongoing severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Objectives: The aim of the study was to assess the impact of COVID-19 on post-transplant renal function and outcome of immunosuppressant management on COVID-19. Patients and Methods: This is a cross sectional observational study conducted from March 2020 to January 2022 in a tertiary care hospital in South India. Baseline characteristics, comorbidities, history of graft dysfunction, symptoms and immunosuppressant modification was noted. Outcomes of COVID-19 such as acute kidney injury (AKI), need for dialysis and post COVID-19 complications were noted. The statistics were expressed as percentage for categorical variables and mean ± SD for continuous variables. Results: Out of 400 renal transplant patients on regular follow up, 28 patients developed COVID-19. The incidence of AKI was 64.2%. Immunosuppressant dose modification was done in majority of patients [mycophenolate mofetil (28.5%), steroids (53.5%) and tacrolimus (39.2%)]. Outcomes included recovery from AKI in 61.1%, recovery from oxygen dependence in 100% patients with an overall mortality rate of 7.1% patients. About 17.8% patients developed post-COVID-19 complications. Conclusion: Immunosuppressant dose modification during COVID-19 could play a role in development of AKI; infection being an independent risk factor. Patients should be monitored for development of post-COVID-19 complications.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of COVID-19 on renal transplant recipients\",\"authors\":\"Ganesan Geethanjali, E. Ramprasad, Sekar Manikantan, M. Jayakumar\",\"doi\":\"10.34172/ipp.2023.39489\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: It was essential to explore immunosuppressant management strategies and potential clinical variables associated with COVID-19 related mortality in order to provide insight for clinicians attempting to manage kidney transplant recipients during the ongoing severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Objectives: The aim of the study was to assess the impact of COVID-19 on post-transplant renal function and outcome of immunosuppressant management on COVID-19. Patients and Methods: This is a cross sectional observational study conducted from March 2020 to January 2022 in a tertiary care hospital in South India. Baseline characteristics, comorbidities, history of graft dysfunction, symptoms and immunosuppressant modification was noted. Outcomes of COVID-19 such as acute kidney injury (AKI), need for dialysis and post COVID-19 complications were noted. The statistics were expressed as percentage for categorical variables and mean ± SD for continuous variables. Results: Out of 400 renal transplant patients on regular follow up, 28 patients developed COVID-19. The incidence of AKI was 64.2%. Immunosuppressant dose modification was done in majority of patients [mycophenolate mofetil (28.5%), steroids (53.5%) and tacrolimus (39.2%)]. Outcomes included recovery from AKI in 61.1%, recovery from oxygen dependence in 100% patients with an overall mortality rate of 7.1% patients. About 17.8% patients developed post-COVID-19 complications. Conclusion: Immunosuppressant dose modification during COVID-19 could play a role in development of AKI; infection being an independent risk factor. Patients should be monitored for development of post-COVID-19 complications.\",\"PeriodicalId\":13454,\"journal\":{\"name\":\"Immunopathologia Persa\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunopathologia Persa\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/ipp.2023.39489\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopathologia Persa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/ipp.2023.39489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:有必要探索与新冠肺炎相关死亡率相关的免疫抑制剂管理策略和潜在临床变量,以便为临床医生在持续的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行期间尝试管理肾移植受者提供见解。目的:本研究的目的是评估新冠肺炎对移植后肾功能的影响以及免疫抑制剂管理对新冠肺炎的结果。患者和方法:这是一项2020年3月至2022年1月在南印度一家三级护理医院进行的横断面观察性研究。记录基线特征、合并症、移植物功能障碍史、症状和免疫抑制剂修饰。注意到新冠肺炎的结果,如急性肾损伤(AKI)、需要透析和新冠肺炎后并发症。统计数据以分类变量的百分比表示,连续变量的平均值±标准差表示。结果:在400名定期随访的肾移植患者中,28名患者出现新冠肺炎。AKI的发生率为64.2%。大多数患者都进行了免疫抑制剂剂量调整[霉酚酸酯(28.5%)、类固醇(53.5%)和他克莫司(39.2%)]。结果包括61.1%的患者从AKI中恢复,100%的患者从氧依赖中恢复,总死亡率为7.1%。约17.8%的患者出现新冠肺炎后并发症。结论:新冠肺炎期间免疫抑制剂剂量的改变可能在AKI的发展中起作用;感染是一个独立的危险因素。应对患者进行COVID-19后并发症的发展监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of COVID-19 on renal transplant recipients
Introduction: It was essential to explore immunosuppressant management strategies and potential clinical variables associated with COVID-19 related mortality in order to provide insight for clinicians attempting to manage kidney transplant recipients during the ongoing severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Objectives: The aim of the study was to assess the impact of COVID-19 on post-transplant renal function and outcome of immunosuppressant management on COVID-19. Patients and Methods: This is a cross sectional observational study conducted from March 2020 to January 2022 in a tertiary care hospital in South India. Baseline characteristics, comorbidities, history of graft dysfunction, symptoms and immunosuppressant modification was noted. Outcomes of COVID-19 such as acute kidney injury (AKI), need for dialysis and post COVID-19 complications were noted. The statistics were expressed as percentage for categorical variables and mean ± SD for continuous variables. Results: Out of 400 renal transplant patients on regular follow up, 28 patients developed COVID-19. The incidence of AKI was 64.2%. Immunosuppressant dose modification was done in majority of patients [mycophenolate mofetil (28.5%), steroids (53.5%) and tacrolimus (39.2%)]. Outcomes included recovery from AKI in 61.1%, recovery from oxygen dependence in 100% patients with an overall mortality rate of 7.1% patients. About 17.8% patients developed post-COVID-19 complications. Conclusion: Immunosuppressant dose modification during COVID-19 could play a role in development of AKI; infection being an independent risk factor. Patients should be monitored for development of post-COVID-19 complications.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
65
审稿时长
3 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信